1. Introduction {#sec1-jcm-08-01676}
===============

Liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide as of 2018. Hepatocellular carcinoma (HCC) comprises 75--85% of primary liver cancer cases \[[@B1-jcm-08-01676]\]. The management of HCC depends on the tumor stage at diagnosis and liver function. Current management strategies involve resection, liver transplantation (LT), radiofrequency ablation (RFA), transarterial embolization (TAE)/transarterial chemoembolization (TACE), radiation therapy, or systemic therapy \[[@B2-jcm-08-01676],[@B3-jcm-08-01676]\]. Patients are considered to have resectable tumors if they have one to three unilobar lesions with an upper limit of 5 cm for a single lesion and 3 cm for more than one lesion; no extrahepatic metastasis or macrovascular invasion; and little or no portal hypertension \[[@B2-jcm-08-01676]\].

Hepatectomy is a potentially curative treatment for HCC, but the long-term prognosis remains unsatisfactory due to the high incidence of recurrence (50--60%) \[[@B4-jcm-08-01676],[@B5-jcm-08-01676],[@B6-jcm-08-01676]\]. Prognostic factors for recurrence and survival after resection include tumor size, α-fetoprotein level, tumor differentiation, microvascular invasion, cirrhosis, surgical margin, and metabolic syndrome \[[@B6-jcm-08-01676],[@B7-jcm-08-01676],[@B8-jcm-08-01676]\]. Recently, the associations between inflammatory markers and the prognosis of HCC have been actively explored, and systemic inflammation has been thought to be related to poor outcomes. The reason is that inflammatory responses play critical roles in tumorigenesis, including initiation, promotion, angiogenesis, invasion, and metastasis \[[@B9-jcm-08-01676]\], and an inflammatory microenvironment is an important condition for tumors \[[@B10-jcm-08-01676]\].

Systemic inflammatory responses have been investigated using markers such as the neutrophil-to-lymphocyte ratio (NLR) \[[@B11-jcm-08-01676],[@B12-jcm-08-01676],[@B13-jcm-08-01676],[@B14-jcm-08-01676]\], platelet to lymphocyte ratio (PLR) \[[@B15-jcm-08-01676],[@B16-jcm-08-01676],[@B17-jcm-08-01676]\], albumin and lymphocyte counts used in the prognostic nutritional index (PNI) \[[@B18-jcm-08-01676],[@B19-jcm-08-01676],[@B20-jcm-08-01676]\], and neutrophil, lymphocyte, and platelet counts used in the systemic immune-inflammation index (SII) \[[@B21-jcm-08-01676],[@B22-jcm-08-01676]\]. To date, most studies have evaluated only one of the inflammatory parameters. Therefore, a comprehensive evaluation of the prognostic values of the inflammatory markers would be valuable for patients with HCC. The aim of this study is to evaluate the effects of inflammatory markers to predict recurrence and survival in HCC patients who have Barcelona Clinic Liver Cancer (BCLC) grades 0--A and are receiving hepatectomy.

2. Materials and Methods {#sec2-jcm-08-01676}
========================

2.1. Ethics Statement {#sec2dot1-jcm-08-01676}
---------------------

The study protocol was approved by the institutional review board and the ethics committee of Chang Gung Memorial Hospital (201901103B0). The ethics committee waived the requirement for informed consent for this study, and all the data were analyzed anonymously.

2.2. Data Sources {#sec2dot2-jcm-08-01676}
-----------------

This retrospective study enrolled patients with newly diagnosed HCC who underwent surgical intervention between January 2001 and June 2016 at Kaohsiung Chung-Gung Memorial Hospital. HCC was diagnosed based on histological evidence or classical imaging features according to the guidelines of the American Association for the Study of the Liver \[[@B23-jcm-08-01676]\]. The staging of tumors was determined according to the BCLC staging classification \[[@B24-jcm-08-01676]\]. Patients who had RFA or TAE before resection, LT after resection, or BCLC stage B or C were excluded from the study ([Figure 1](#jcm-08-01676-f001){ref-type="fig"}). Surgical resection for tumors in BCLC stage 0 or A is the widely accepted standard treatment. However, surgical treatment for BCLC stage B or C HCC remains controversial. Recently, the management of HCC has tended to involve a multidisciplinary approach, such as RFA or TACE combined with surgery, etc. Because RFA and TACE are associated with the induction of inflammation and immunological responses, it might have some degree of influence on inflammatory indicators. Hence, only treatment-naïve HCC patients were enrolled in our study. LT was believed to cure both the tumor and the underlying cirrhosis at the same time in well-selected patients, which also have an influence on the survival. Therefore, those who received salvage LT were excluded \[[@B25-jcm-08-01676]\].

2.3. Methods {#sec2dot3-jcm-08-01676}
------------

Patient demographics and clinical characteristics were obtained from the reviewed medical records, including complete blood counts, albumin, α-fetoprotein level, Child--Turcotte--Pugh (CTP) class, date of diagnosis, status of viral hepatitis, tumor staging by BCLC, duration of follow-up, and outcomes. Blood tests were taken within 1 week before operation. NLR was calculated by dividing the absolute neutrophil count by the lymphocyte count, and PLR was obtained by dividing the platelet count by the lymphocyte count. PNI was calculated using the following equation: lymphocyte count (/μL) × 0.005 + albumin (g/dL) × 10. SII was measured as platelet count × neutrophil count/lymphocyte count (/μL) \[[@B26-jcm-08-01676]\]. Recurrence-free survival (RFS) was defined as the period from tumor removal by resection until the detection of recurrent or metastatic disease. Overall survival (OS) was defined as the time from the diagnosis to death, last contact, or 28 February 2017.

2.4. Statistical Analysis {#sec2dot4-jcm-08-01676}
-------------------------

Descriptive analyses were used to determine the patients' clinicopathological characteristics at baseline. Kaplan--Meier survival curves were constructed for each variable. A Cox proportional hazard model was used for the multivariate analysis of the hazard ratio (HR). All statistical analyses were conducted using software SPSS Version 23.0. (IBM Corp., Armonk, NY, USA) A two-sided *p* value \< 0.05 was considered significant.

3. Results {#sec3-jcm-08-01676}
==========

3.1. Clinical Characteristics {#sec3dot1-jcm-08-01676}
-----------------------------

A total of 2137 patients received hepatectomy for HCC between January 2001 and June 2016. Overall, 1246 patients were excluded due to intermediate to advanced stages (BCLC stage B or C) (*n* = 918), RFA or TAE before operation (*n* = 234), and liver transplantation after resection (*n* = 94). The remaining 891 patients were eligible for the analysis ([Figure 1](#jcm-08-01676-f001){ref-type="fig"}).

The mean age was 58.53 years, and the majority of patients were men (*n* = 694, 77.9%). There were 239 patients (27.8%) who were diabetic before surgery, and 417 patients (46.8%) were diagnosed with cirrhosis. Cirrhosis was defined as METAVIR stage 4 fibrosis based on reports of the histopathological evaluation of non-tumor liver tissue obtained by surgery at the time of the resection of the tumor \[[@B27-jcm-08-01676]\]. Most patients were classified as CTP A (*n* = 819, 91.9%). The median follow-up time was 5.30 ± 3.04 years, and a total of 433 (48.6%) patients had recurrent disease during follow-up ([Table 1](#jcm-08-01676-t001){ref-type="table"}).

3.2. Optimal Cutoff Values for Inflammatory Markers {#sec3dot2-jcm-08-01676}
---------------------------------------------------

Each inflammatory marker was stratified according the maximum sensitivity and specificity using Youden's index. The optimal cutoff value for NLR was 1.8 (AUROC curve: 0.539; 95% confidence interval (CI): 0.501--0.577). The optimal cutoff value for PLR was 116.6 (AUROC curve: 0.509; 95% CI: 0.471--0.546). The optimal cutoff value for PNI was 42.8 (AUROC curve: 0.663; 95% CI: 0.626--0.698). The optimal cutoff value for SII was 160.0 (AUROC curve: 0.514; 95% CI: 0.476--0.551) ([Table 2](#jcm-08-01676-t002){ref-type="table"} and [Figure 2](#jcm-08-01676-f002){ref-type="fig"}).

3.3. Survival Analysis {#sec3dot3-jcm-08-01676}
----------------------

The one- and five-year OS rates were 97 and 82%, respectively. As shown in [Table 3](#jcm-08-01676-t003){ref-type="table"}, old age (\>60 years old; *p* = 0.024), diabetes mellitus (*p* \< 0.001), cirrhosis (*p* \< 0.001), microvascular invasion (*p* \< 0.001), high AFP (\> 5 μg/L; *p* = 0.047), high NLR (\>1.8; *p* = 0.032), low PNI (≤45; *p* \< 0.001), and low SII (≤160; *p* = 0.008) were associated with high OS in BCLC 0-A HCC patients after hepatectomy. The relationships of NLR, PNI, and SII with OS and RFS are shown in [Figure 3](#jcm-08-01676-f003){ref-type="fig"}. High NLR was significantly associated with poor OS (*p* = 0.032). However, high PNI was significantly associated with better OS (*p* \< 0.001) and RFS (*p* \< 0.001). In addition, elevated SII was associated with better OS (*p* = 0.008) and RFS (*p* \< 0.001). The one-year, three-year, and five-year OS rates of patients with PNI \> 45 and SII \> 160 were 99%, 96%, and 90% respectively, which were significantly higher than those observed with PNI ≤ 45 and SII ≤ 160 (90%, 77%, and 66%) ([Figure 4](#jcm-08-01676-f004){ref-type="fig"}).

In the univariate analysis, old age (\>60 years old), HCV infection, HBV and HCV coinfection, diabetes mellitus, cirrhosis, microvascular infection, high AFP (\>5 μg/L), high NLR (\>1.8), low PNI (≤45), and low SII (160 × 10^9^/L) were associated with poor OS. The multivariate analysis of these parameters revealed that diabetes mellitus, cirrhosis, microvascular infection, low PNI (≤45), and low SII (≤160 × 10^9^/L) were independently associated with poor OS. The HR of death for low PNI was 1.789 (95% CI 1.217--2.630, *p* = 0.003), and that for low SII was 1.674 (95% CI 1.097--2.552, *p* = 0.017) ([Table 4](#jcm-08-01676-t004){ref-type="table"}).

Overall, 458 patients (51.4%) were free from tumor relapse during the follow-up period, and the mean time to recurrence was 3.80 ± 3.17 years. The one- and five-year RFS rates were 80 and 51%, respectively. The univariate analysis showed that poor RFS was also associated with old age (\>60 years old), HCV infection, HBV and HCV coinfection, diabetes mellitus, cirrhosis, microvascular invasion, high AFP (\> 5 μg/L), low PNI (≤45), and SII (≤160 × 10^9^/L). The multivariate analysis demonstrated that HCV infection, diabetes mellitus, cirrhosis, microvascular invasion, low PNI (≤45), and low SII (≤160 × 10^9^/L) were independent prognostic factors for RFS. The HR of tumor recurrence for low PNI was 1.378 (95% CI 1.092--1.738, *p* = 0.007), and that for low SII was 1.616 (95% CI 1.231--2.123, *p* = 0.001) ([Table 5](#jcm-08-01676-t005){ref-type="table"}).

The relationship between inflammatory markers and clinicopathological features is summarized in [Table 6](#jcm-08-01676-t006){ref-type="table"}; [Table 7](#jcm-08-01676-t007){ref-type="table"}. Low PNI (≤45) was associated with old age (*p* \< 0.001), HCV infection (*p* \< 0.001), raised alanine aminotransferase (ALT) (*p* \< 0.001), decreased albumin (*p* \< 0.001), and raised INR (*p* \< 0.001). SII ≤ 160 was associated with raised INR (*p* \< 0.001) and microvascular invasion (*p* = 0.034).

4. Discussion {#sec4-jcm-08-01676}
=============

Surgical resection is the mainstay of curative treatment for very-early and early-stage HCC with preserved liver function. Tumor recurrence is still the main concern of resection, and the five-year cumulative HCC recurrent rates are more than 50% \[[@B2-jcm-08-01676],[@B28-jcm-08-01676]\]. Many studies have shown the relationships between inflammatory response and the development of tumors, and several scoring systems have been developed to predict the prognosis in cancer patients. NLR, PLR, PNI, and SII have been reported to be useful in predicting OS and recurrence in HCC patients.

We investigated the clinical and prognostic value of these widely used inflammatory markers in early-stage HCC patients receiving operation and compared their predictive accuracy. Our retrospective cohort of 891 patients revealed that PNI and SII are independent predictors of OS and tumor recurrence. Furthermore, the predictive power of the PNI score outweighs that of other inflammatory markers. PNI and SII are derived from routinely available blood tests, making them easy to apply in routine clinical practice to predict the prognosis in HCC patients.

Studies have shown that the systemic inflammatory response as measured by the NLR, PLR, and SII are good predictors of tumor outcomes. The exact mechanism remains unclear, but several hypotheses have been proposed. Basic studies have revealed that neutrophils can induce tumor proliferation and angiogenesis, as well as enhance the migration and metastasis of cancer cells. In addition, HCC cells induce neutrophils to release hepatocyte growth factor, which makes cancer cells become more aggressive \[[@B29-jcm-08-01676]\]. Platelets can be activated by immune cells and cancer cells and play an important role in tumor metastasis, tumor growth, and angiogenesis. This occurs by protecting cancer cells from immune surveillance, facilitating cancer cell arrest within the vasculature and subsequent tissue invasion, inducing endothelial cell proliferation and new blood vessel formation, and interacting with cancer cells and stroma in the tumor microenvironment \[[@B30-jcm-08-01676]\]. However, lymphocytes, including T cells, B cells, and natural killer cells, have antitumor effects either directly or upon the activation of other lymphocytes \[[@B31-jcm-08-01676]\].

Higher levels of NLR and PLR are associated with poor outcomes in many types of cancer. In a meta-analysis of patients with HCC, Zeng et al. examined 24 studies and concluded that a high NLR predicted a poor OS (HR: 1.54, 95% CI 1.34--1.76, *p* \< 0.001) and poor RFS (HR: 1.45, 95% CI 1.16--1.82, *p* = 0.001), while a high PLR predicted poor OS (HR: 1.63, 95% CI 1.34--1.98, *p* \< 0.001) and poor RFS (HR: 1.52, 95% CI 1.21--1.91, *p* \< 0.001) \[[@B32-jcm-08-01676]\]. In the present study, a high NLR (\>1.8) before surgical resection predicted poor OS in HCC patients, but NLR was not an independent factor in predicting OS and RFS in the multivariate analyses. PLR had no significant association with OS or RFS.

Higher SII has been reported to be a poor prognostic factor in multiple cancers. A recent meta-analysis included 22 studies with 7657 patients and showed that a higher level of SII was correlated with poor OS (HR: 1.69, 95% CI 1.42--2.01, *p* \< 0.001) and poor RFS (HR = 1.66, *p* = 0.025) in patients with cancers. Furthermore, a subgroup analysis revealed that higher SII than a cutoff value could predict poor OS in HCC (*p* \< 0.001) \[[@B33-jcm-08-01676]\]. However, our study revealed the opposite result: low SII predicted a poor prognosis of OS (HR: 1.674, 95% CI 1.097--2.552, *p* = 0.017) and RFS (HR: 1.616, 95% CI: 1.231--2.123, *p* = 0.001). Lower SII means lower neutrophil levels, lower platelet levels, and higher lymphocyte levels, as shown in [Table 7](#jcm-08-01676-t007){ref-type="table"}. Thrombocytopenia was an independent predictor for survival in patients with compensated cirrhosis and HCC treated with hepatectomy \[[@B34-jcm-08-01676]\]. Through a meta-analysis, Zhang et al. showed that thrombocytopenia in HCC patients was associated with poor OS (HR: 1.47, 95% CI 1.21--1.78) and poor RFS (HR: 1.41, 95% CI: 1.22--1.62) in HCC patients after hepatic resection \[[@B35-jcm-08-01676]\]. Platelet count has been used to assess the severity of chronic liver disease and features of portal hypertension \[[@B36-jcm-08-01676]\]. In the present study, low SII was associated with high APRI and high INR, which are related to significant fibrosis and poor liver function. In the subgroup analysis stratified by platelet count, low SII in the thrombocytopenia group revealed significantly poor OS (*p* = 0.019) and RFS (*p* = 0.002) compared to those with high SII, but there was no statistical significance in the non-thrombocytopenia group. Therefore, low SII is associated with poor outcome due to advanced liver disease, especially in those with thrombocytopenia.

The PNI was initially designed to assess the immunological and nutritional condition of patients undergoing surgery for digestive diseases \[[@B37-jcm-08-01676]\]. It was first used to predict HCC outcome as an inflammatory marker by Pinato et al. in 2012 \[[@B18-jcm-08-01676]\]. Lymphopenia is an unfavorable prognostic factor for OS in several cancers \[[@B38-jcm-08-01676]\], which may result from an increased rate of turnover of lymphocytes induced by tumor cells \[[@B39-jcm-08-01676]\] or an altered homeostasis of lymphocytes in patients with tumors \[[@B40-jcm-08-01676]\]. Albumin synthesis is reduced by the systemic inflammatory response to a tumor \[[@B41-jcm-08-01676]\], although impaired hepatic synthetic function in advanced liver disease also needs to be considered as an additional cause for reduced serum albumin. Chan et al. reported that the PNI was a significant predictor for OS and RFS in patients with very-early/early-stage HCC receiving curative surgery \[[@B20-jcm-08-01676]\]. Our data are consistent with previous studies suggesting that low PNI predicts poor OS and RFS in HCC patients receiving hepatectomy. We subsequently compared the predictive power of the PNI with other inflammatory markers, including NLR, PLR, and SII, and the PNI produced superior results.

Nevertheless, there are some limitations to our study. First, it is a retrospective study with patients from a single institution, which could lead to biases. Second, more than half of the patients in the study had HBV infection as the etiology of HCC, whereas chronic HCV infection is the major cause for the development of HCC in Western countries and Japan \[[@B42-jcm-08-01676]\]. Moreover, laboratory values were only collected before surgery, and a serial follow-up of inflammatory markers after surgery may provide more insights in the prognostic values.

In conclusion, among the evaluated preoperative serum inflammatory markers, low PNI and low SII were independently associated with unfavorable outcomes of OS and RFS in patients with BCLC 0-A hepatocellular carcinoma after hepatectomy. Those observed with low PNI or low SII, especially PNI ≤ 45 and SII ≤ 160 with a high one-year recurrence rate (50%), need a close follow-up, and further adjuvant therapies, such as target or immune-based therapy, might be required. However, the side effects of drugs should be watched for, and additional well-designed studies are needed to confirm this concept. Further evaluation of these markers should be performed on a larger scale and compared between different patient populations.
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![Flow chart of patients included in this study. HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer.](jcm-08-01676-g001){#jcm-08-01676-f001}

![Comparisons of the areas under the curve (AUC) for outcome predictions in patients after operations.](jcm-08-01676-g002){#jcm-08-01676-f002}

![Relationship of (**A**) neutrophil-to-lymphocyte ratio (NLR), (**B**) prognostic nutrition index (PNI), and (**C**) systemic Immune-Inflammation Index (SII) to overall survival (OS), as well as recurrent free survival (RFS).](jcm-08-01676-g003){#jcm-08-01676-f003}

![Relationship of prognostic nutrition index (PNI) and systemic Immune-Inflammation Index (SII) to (**A**) overall survival (OS) and (**B**) recurrence-free survival. Group 0 = PNI \> 45 and SII \> 160, group 1 = PNI \> 45/SII ≤ 160 or PNI ≤ 45/SII \> 160, group 2 = PNI ≤ 45 and SII ≤ 160.](jcm-08-01676-g004){#jcm-08-01676-f004}

jcm-08-01676-t001_Table 1

###### 

Patients' baseline characteristics before hepatectomy.

  Number of Patients                   891
  ------------------------------------ -----------------
  Median follow-up (Years)             5.30 ± 3.04
  Mean Age (Years)                     58.54 ± 11.60
  HBV Infection. *n* (%)               502 (56.3)
  HCV Infection. *n* (%)               311 (34.9)
  HBV + HCV Coinfection. *n* (%)       44 (4.9)
  Male. *n* (%)                        694 (77.9)
  Diabetes Mellitus. *n* (%)           239 (27.8)
  AFP \> 5 ng/mL. *n* (%)              601 (67.5)
  Cirrhosis. *n* (%)                   417 (46.8)
  Child--Turcotte--Pugh. *n* (%)       
  A                                    819 (91.9)
  B                                    71 (8)
  BCLC Stage. *n* (%)                  
  0                                    125 (14)
  A                                    766 (86)
  Tumor Differentiation. *n* (%)       
  Well                                 111 (12.5)
  Moderate                             743 (83.4)
  Poor                                 24 (2.7)
  HCC Recurrence. *n* (%)              433 (48.6)
  Mean time to Recurrence (years)      3.80 ± 3.17
  Mean NLR Before Surgery              2.81 ± 3.99
  NLR \> 1.8 before Surgery. *n* (%)   338 (47.7)
  Mean PLR before Surgery              102.14 ± 67.97
  PLR \> 120 before Surgery. *n* (%)   178 (25.2)
  Mean PNI before Surgery              44.18 ± 7.38
  PNI ≤ 45 before Surgery. *n* (%)     441 (55.1)
  Mean SII before Surgery (×10^9^/L)   442.23 ± 680.78
  SII ≤ 160 before Surgery. *n* (%)    144 (20.5)

Data are expressed as mean ± standard deviation or number (percentage). Abbreviations: HBV: hepatitis B virus; HCV: hepatitis C virus; AFP: alpha-fetoprotein; BCLC stage: Barcelona clinic liver cancer stage; HCC: hepatocellular carcinoma; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; SII: systemic immune-inflammation index.

jcm-08-01676-t002_Table 2

###### 

Comparisons of the areas under the curve (AUC) values and the cutoff values among the inflammatory markers.

            AUC     CUTOFF    SE      95% CI
  --------- ------- --------- ------- --------------
  **NLR**   0.539   1.809     0.028   0.501--0.577
  **PLR**   0.509   116.618   0.029   0.471--0.546
  **PNI**   0.663   42.844    0.026   0.626--0.698
  **SII**   0.514   159.984   0.029   0.476--0.551

Neutrophil-to-lymphocyte ratio (NLR) = Neutrophil/lymphocyte, platelet to lymphocyte ratio (PLR) = platelet/lymphocyte, Prognostic nutritional index (PNI) = lymphocyte(/μL) × 0.005 + albumin (g/dL) × 10, Systemic Immune-Inflammation Index (SII) = Neutrophil × platelet/lymphocyte.

jcm-08-01676-t003_Table 3

###### 

Cumulative survival rates in BCLC 0-A HCC patients after hepatectomy.

  Variables                Patient No.   1 Year (%)   3 Years (%)   5 Years (%)   *p* Value
  ------------------------ ------------- ------------ ------------- ------------- -----------
  Age (Years)                                                                     
  \>60                     464           96.7         89.2          78.2          0.024
  ≤60                      427           97.6         93.9          85.5          
  Gender                                                                          
  Male                     694           96.9         92.0          82.4          0.792
  Female                   197           98.0         89.3          79.4          
  Diabetes Mellitus                                                               
  Yes                      239           97.0         88.8          72.3          \<0.001
  No                       621           97.1         92.5          84.9          
  Liver Cirrhosis                                                                 
  Yes                      417           95.7         87.5          75.9          \<0.001
  No                       474           98.5         94.9          86.8          
  Differentiation                                                                 
  Moderate or Poor         767           97.0         91.3          81.2          0.201
  Well                     111           98.2         91.4          84.8          
  Microvascular Invasion                                                          
  Yes                      330           94.5         87,2          75.5          \<0.001
  No                       561           98.7         94.0          85.3          
  Serum AFP (μg/L)                                                                
  \>5                      601           96.5         90.5          80.3          0.047
  ≤5                       234           98.7         95.0          86.9          
  NLR                                                                             
  \>1.8                    338           96.4         89.8          77.2          0.032
  ≤1.8                     370           97.3         91.5          83.0          
  PLR                                                                             
  \>120                    178           96.1         89.2          75.7          0.169
  ≤120                     529           97.1         91.2          81.8          
  PNI                                                                             
  \>45                     359           97.8         95.0          88.2          \<0.001
  ≤45                      441           96.3         87.6          75.2          
  SII (×10^9^/L)                                                                  
  \>160                    559           97.8         92.3          82.1          0.008
  ≤160                     144           93.0         84.2          73.2          

Abbreviations: HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; SII: systemic immune-inflammation index.

jcm-08-01676-t004_Table 4

###### 

Uni-and multivariate analyses of factors associated with mortality by Cox proportional hazards model.

                                  Univariate   Multivariate                                    
  ------------------------------- ------------ -------------- --------- ------- -------------- ---------
  Male Sex                        1.050        0.728--1.516   0.793                            
  Age (\>60 Years)                1.601        1.173--2.187   0.003                            
  HBV Infection                   0.922        0.562--1.514   0.794                            
  HCV Infection                   1.347        0.810--2.240   0.251                            
  HBV + HCV Coinfection           1.532        0.748--3.134   0.243                            
  Diabetes Mellitus               2.066        1.499--2.848   \<0.001   1.989   1.362--2.906   \<0.001
  Cirrhosis                       1.978        1.442--2.713   \<0.001   1.502   1.013--2.227   0.043
  Moderate/poor Differentiation   1.367        0.836--2.235   0.213                            
  Microvascular Invasion          2.040        1.427--2.915   \<0.001   1.642   1.123--2.401   0.011
  AFP \> 5 μg/L                   1.541        1.044--2.276   0.030                            
  NLR \> 1.8                      1.441        1.029--1.071   0.033                            
  PLR \> 120                      1.287        0.898--1.845   0.170                            
  PNI ≤ 45                        1.976        1.401--2.788   \<0.001   1.789   1.217--2.630   0.003
  SII ≤ 160 (×10^9^/L)            1.654        1.137--2.405   0.008     1.674   1.097--2.552   0.017

Abbreviations: HR: hazard ratio; CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; AFP: alpha-fetoprotein; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; SII: systemic immune-inflammation index.

jcm-08-01676-t005_Table 5

###### 

Uni- and multivariate analyses of factors associated with recurrence by Cox proportional hazards model.

                                  Univariate   Multivariate                                    
  ------------------------------- ------------ -------------- --------- ------- -------------- ---------
  Male Sex                        0.978        0.779--1.228   0.848                            
  Age (\>60 Years)                1.382        1.144--1.670   0.001                            
  HBV Infection                   1.214        0.885--1.665   0.230                            
  HCV Infection                   1.651        1.189--2.293   0.003     1.298   1.022--1.649   0.033
  HBV + HCV Coinfection           1.880        1.164--3.036   0.010                            
  Diabetes Mellitus               1.368        1.110--1.687   0.003     1.352   1.05--1.734    0.017
  Cirrhosis                       1.762        1.457--2.132   \<0.001   1.536   1.21--1.950    \<0.001
  Moderate/Poor Differentiation   1.005        0.760--1.329   0.972                            
  Microvascular Invasion          1.653        1.325--2.062   \<0.001   1.542   1.218--1.951   \<0.001
  AFP \> 5 μg/L                   1.398        1.116--1.752   0.004                            
  NLR \> 1.8                      0.972        0.786--1.203   0.797                            
  PLR \> 120                      0.975        0.765--1.243   0.839                            
  PNI ≤ 45                        1.462        1.195--1.790   \<0.001   1.378   1.092--1.738   0.007
  SII ≤ 160 (×10^9^/L)            1.751        1.372--2.234   \<0.001   1.616   1.231--2.123   0.001

Abbreviations: HR: hazard ratio; CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; AFP: alpha-fetoprotein; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet to lymphocyte ratio; PNI: prognostic nutritional index; SII: systemic immune-inflammation index.

jcm-08-01676-t006_Table 6

###### 

Comparison of characteristics between patients with high and low PNI.

                                  High PNI (\>45, *n* = 362)   Low PNI (≤45, *n* = 444)   *p* Value
  ------------------------------- ---------------------------- -------------------------- -----------
  Male Sex                        294 (81.2%)                  338 (76.1%)                0.086
  Age, Years                      55.67 ± 12.23                60.83 ± 10.79              \<0.001
  HBV Infection                   228 (63.0%)                  230 (51.8%)                0.002
  HCV Infection                   95 (26.2%)                   187 (42.1%)                \<0.001
  APRI                            0.61 ± 0.47                  1.24 ± 2.01                \<0.001
  ALT, U/L                        42.24 ± 26.79                63.61 ± 103.31             \<0.001
  Neutrophil, /μL                 3240.26 ± 1210.93            4181.64 ± 3668.09          \<0.001
  Lymphocyte, /μL                 2109.12 ± 641.08             1445.07 ± 560.36           \<0.001
  Platelet, ×10^3^/μL             170.90 ± 55.62               151.95 ± 89.63             0.001
  Total Bilirubin, mg/dL          0.80 ± 0.30                  0.83 ± 0.36                0.171
  Albumin, g/dL                   4.07 ± 0.40                  3.30 ± 0.54                \<0.001
  Prothrombin Time, INR           1.02 ± 0.056                 1.05 ± 0.96                \<0.001
  Moderate/Poor Differentiation   314 (89.0%)                  376 (85.6%)                0.200
  Microvascular Invasion          130 (46.4%)                  158 (48.9%)                0.568
  AFP, μg/L                       416.47 ± 1620.65             661.87 ± 3242.02           0.195

Data are expressed as mean ± standard deviation or number (percentage). Abbreviations: PNI: prognostic nutritional index; HBV: hepatitis B virus; HCV: hepatitis C virus; APRI: aspartate aminotransferase to platelet ratio index; ALT: alanine aminotransferase; INR: international normalized ratio; AFP: alpha-fetoprotein.
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###### 

Comparison of characteristics between patients with high and low SII.

                                  High SII (\>160, *n* = 559)   Low SII (≤160, *n* = 144)   *p* Value
  ------------------------------- ----------------------------- --------------------------- -----------
  Male Sex                        452 (80.9%)                   101 (70.1%)                 0.006
  Age, Years                      58.87 ± 11.66                 58.41 ± 11.46               0.672
  HBV Infection                   316 (56.5%)                   81 (56.3%)                  1.000
  HCV Infection                   191 (34.2%)                   60 (41.7%)                  0.098
  APRI                            0.84 ± 1.60                   1.32 ± 1.00                 0.001
  ALT, U/L                        53.62 ± 91.86                 56.50 ± 39.24               0.714
  Neutrophil, /μL                 4193.03 ± 2970.90             2004.19 ± 611.43            \<0.001
  Lymphocyte, /μL                 1713.61 ± 651.65              1977.01 ± 780.13            \<0.001
  Platelet, ×10^3^/μL             171.02 ± 80.96                115.46 ± 41.09              \<0.001
  Total bilirubin, mg/dL          0.80 ± 0.34                   0.81 ± 0.30                 0.822
  Albumin, g/dL                   3.62 ± 0.61                   3.50 ± 0.60                 0.054
  Prothrombin Time, INR           1.03 ± 0.07                   1.06 ± 0.10                 \<0.001
  Moderate/Poor Differentiation   480 (87.9%)                   131 (91.0%)                 0.377
  Microvascular Invasion          211 (53.0%)                   67 (65.0%)                  0.034
  AFP, μg/L                       516.49 ± 2293.49              873.22 ± 4145.54            0.175

Data are expressed as mean ± standard deviation or number (percentage). Abbreviations: SII: systemic immune-inflammation index; HBV: hepatitis B virus; HCV: hepatitis C virus; APRI: aspartate aminotransferase to platelet ratio index; ALT: alanine aminotransferase; INR: international normalized ratio; AFP: alpha-fetoprotein.
